Blog / Archives
Gilead (GILD) $11B Deal for Pharmasset (VRUS) Sparks Biotech Stocks
Pharmasset Buyout Brings To Mind M&A Upside for Biotech Stocks: ETF's and Funds Lead the Way Gilead (GILD $35) stepped up with a huge buyout of Pharmasset (VRUS $134.21) driving the stock up 89%...
Caution on Biotechs With Risk Off Situation-UPDATE 1/5/12 Dendreon Soars
Dendreon (DNDN $10.94) soared 44% today on a business update saying Provenge sales for its prostate cancer treatment were better than expected. Fourth quarter gross revenues were $82M with full year...
Fidelity Biotech Fund (FBIOX) up 7.9% YTD Outperforms Major ETFs
Managed Healthcare Mutual Funds Starting To OutPerform ETFs Earlier this year we wrote an article on Investor Uprising comparing returns on biotech funds and major ETFs. At the time ETF's were...
Macro Rules: Gold Gains Strength As Fiat Currency Update – 1
Volatile schizoid markets- Not a Good Time to Add Positions in the Life Sciences It is very hard to focus on biotech stocks with all the financial distress and chaos in the Eurozone dominating the...
MFGlobal: Where is the Customer Money?
Many of you read about the bankruptcy of MFGlobal last week. What you may not know is that customers still cannot access their cash.If they have open positions they have been transferred to...
BIO Investor Forum: Oct 26,27
We attended the BIO Investor Forum in San Francisco last week and here is my brief summary of funding, important trends and technologies. Investor Uprising – Rod Raynovich – Biotech Bull Market...
Rayno Life Science Portfolio Winners: BMRN,GILD,QQQ, VPHM
We attended the BIO Investor Forumin San Francisco this week and will provide a brief review of select technologies and companies on Monday. Despite a funding gap for earlier stage companies we...
Rayno Life Science Portfolio Movers: ALXN, AMRI, CBST
Rayno Life Science picks had earnings news and overall the Portfolio was up 1%. Albany Molecular (AMRI $3.49) stock was up 5.44% on low volume but showing steady recovery from recent lows in the $3...
Phase 3 Malaria Vaccine Trial Effective: AGEN, GSK
A promising new malaria vaccine from GlaxoSmithKline (GSK $43.72) offers hope to children in Africa.The final stage trial cut the risk of clinical malaria by 56 % and severe malaria by 47%. Malaria...
Another Big Rally on Europe Non-News: Biotech Sector Lagging
Another stealth rally led by financials took the S&P 500 up 2% helped by a turbo boost in the last 90 minutes as The Guardian reported that France and Germany agreed to boost the rescue fund.Oil...